Liminal BioSciences Inc. LMNL

Plan as recently stated by MGMT

[GunnerG]

What management is presenting, are separte events in a bulleted list.

Listed point 1 is the "anticipated filing of BLA".  No guarantee, management is anticipating its sumbmission.  Definition of anticipated - "regard as probable; predict.".  Remember, they haven't got the FDA required checks in place and its been two years.

Listed point 2, "expected completion" of partnership.  No guarantee of a partnership they are hopeful to get a deal. 

Also, you failed to highlight the most critical part of point 2; "if approval received".  Management is stating a partnership is hopeful; if the FDA approval is received.

Point 1 is a separate event, ie filing BLA.

Point 2 is another event, totally separate from the first.

Key Corporate and R&D Priorities for 2020

• Anticipated filing of an amended BLA with FDA for Ryplazim for the treatment of congenital plasminogen deficiency in the first half of the year
• Expected completion of a global marketing partnership for Ryplazim, and preparation for commercial launch of Ryplazim in the United States, if approval is received

[GoBBs]

1/ re-file ...2/ approval ...3/ partnership ...in that order ...even if they filed it tommorrow it could take 6months fastracked before they could partner it by their own admission....so earliest if they file it tommorrow July 13th ... PLI's non-NR's need to read very carefully and you will see the truth.  Geez they haven't even said if the checkpoints are complete and if they are

[ernieballs77]

This post has been removed in accordance with Community Policy

[Newcamo]

This post has been removed in accordance with Community Policy